Hepatocellular carcinoma (HCC) · Sofosbuvir/Velpatasvir 12 weeks

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`REG-DAA-SOF-VEL`

ID	`IND-CHRONIC-HCV-HBV-COINFECTION-PREVENTION-COMBINATION-ANTIVIRAL`
Type	Indication
Status	reviewed 2026-05-18 \| pending_clinical_signoff
Diseases	`DIS-HCC`
Sources	`SRC-AASLD-HBV-2024` `SRC-AASLD-HCC-2023` `SRC-AASLD-IDSA-HCV-2023` `SRC-EASL-HBV-2025` `SRC-EASL-HCV-2023`

Notes

STUB — HCV+HBV coinfection prevention anchor. v0.2-A continuation.

Used By

Indication

IND-CHRONIC-HCV-HBV-COINFECTION-PREVENTION-OBSERVATION - IND-CHRONIC-HCV-HBV-COINFECTION-PREVENTION-OBSERVATION